Luxeptinib is a small molecule commercialized by Aptose Biosciences, with a leading Phase I program in Relapsed Acute Myeloid Leukemia. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Luxeptinib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Luxeptinib is expected to reach an annual total of $82 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
CG-806 is under development for the treatment of relasped/refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), r/r chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom Macroglobulinemia, mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. It is a pan-FLT3/BTK inhibitor and act by targeting FLT3 (FMS-like tyrosine kinase 3) and brew button tyrosine kinase (bruton tyrosine kinase, BTK) along with CSF1R, PDGFRα, TRK, AURK, others. It is administered through the oral route. The drug candidate is developed based on a combination of soluble protein solution (SPS), structural chemo proteomics (SCP), structural-based drug factory (SDF) platforms.
Aptose Biosciences Overview
Aptose Biosciences (Aptose) is a clinical-stage biotechnology company that focuses on developing personalized therapies for the treatment of life-threatening cancers including, acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), certain B-cell malignancies, and other hematologic malignancies. The company’s cancer therapeutics pipeline products include HM43239, a myeloid kinome inhibitor (MKI), CG-806, a FLT3/BTK kinase inhibitor; APTO-253, a MYC oncogene inhibitor and APL-581, a dual BET Bromodomain-Kinase Inhibitor. Its small molecule cancer therapeutics pipeline product programs are designed to provide single agent benefit. The company operates in Canada and the US and has collaborations with biopharmaceutical companies and healthcare centers for the development and commercialization of its pipeline product programs. Aptose is headquartered in San Diego, California, the US.
The operating loss of the company was US$42.6 million in FY2022, compared to an operating loss of US$65.5 million in FY2021. The net loss of the company was US$41.8 million in FY2022, compared to a net loss of US$65.4 million in FY2021.
For a complete picture of Luxeptinib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.